Evidence map›Paper›PMID 19751315›Full record

ArticleBritish journal of pharmacology2009

Ezetimibe - new anti-atherogenic properties?

Gerald H Tomkin

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gerald H TomkinDiabetes Institute of Ireland, Beacon Clinic, Dublin, Ireland. gerald.tomkin@tcd.ie
Molecular Medicine Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ezetimibe, a Niemann Pick C1-like1 inhibitor, inhibits cholesterol absorption. The drug has been shown to affect lipid raft function in monocytes and therefore may inhibit lipid accumulation in the atheromatous plaque with a mechanism that is unrelated to its effect in reducing cholesterol absorption. In this issue of the British journal of pharmacology, Gómez-Garre et al. demonstrate that ezetimibe and simvastatin both have a beneficial effect on the atheromatous plaque, which may be due to their effect on both monocyte/macrophage function and reduction in nuclear factor-kappaB activity. Whether these results in a rabbit model of atherosclerosis can be translated into human atherosclerosis awaits further studies.

Indexed as

AnimalsAnticholesteremic AgentsAtherosclerosisAzetidinesCell MovementChemokine CCL2C-Reactive ProteinDisease Models, AnimalDrug Therapy, CombinationEzetimibeFemoral ArteryHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationInflammation MediatorsLipidsAnticholesteremic AgentsAzetidinesChemokine CCL2C-Reactive ProteinEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsLipidsNF-kappa BSimvastatin

Identifiers

PMID19751315
PMCPMC2697731
OpenAlexW1566747594

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.